Latest Operations News

Macquarie Core Global Equity Fund (ASX:MQE) reported a sharp rise in FY2026 operating profit as net assets more than tripled and the portfolio expanded. The result reflects both substantial new applications and investment gains, rather than investment performance alone.

Benjamin Hornigold Limited (ASX:BHD) delivered a 9.93% portfolio return in FY2026 but still posted a $420,931 loss after $565,697 in legal fees. Two settlements worth $2.6 million were received after year-end, while an $8.97 million judgment against JB Markets was assigned no value.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Emperor Energy has secured NOPSEMA approval for the Judith-2 appraisal well, removing a major regulatory barrier ahead of targeted drilling in April 2027. The well will test a 166 Bcf contingent gas resource and investigate deeper prospective sands, although commercial conversion remains unproven.

Atlas Arteria has warned that France may more than double the tax rate applied to eligible toll-road operators, with APRR’s 2025 TEILD bill already reaching €126.7 million. The proposed changes remain subject to parliamentary debate and could be softened before becoming law.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Silver Mines has built a substantially larger economic case for Bowdens, but the project still needs NSW approval before its 93.5 million ounce reserve can become a mine. The company is now funding the next phase with a A$70 million placement while absorbing dilution and a major royalty buy-back.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

Larvotto Resources has extended high-grade antimony-gold-tungsten mineralisation at Clarks Gully about 100 metres beyond its 2025 resource model, with drilling also identifying several hanging-wall lodes. The results could support a larger resource and a potential underground feed source for Hillgrove, but assays, modelling and permitting work remain outstanding.

Felix Gold advanced bulk extraction, processing and refinery plans at its Alaska antimony project in FY26, but the push came with a larger loss, falling cash and an auditor-documented material uncertainty over going concern. A potential US$18 million Department of Energy award remains subject to negotiation rather than a committed funding source.

Accelerate Resources enters FY2027 with high-grade manganese targets at Woodie Woodie North and new gold zones at Balagundi, but a sharp annual loss and ongoing funding needs remain part of the story. The company plans maiden and follow-up drilling while seeking shareholder approval to rename itself Mango Metals.

AnteoTech has set sales conversion as its FY2027 priority after FY2026 sales revenue slipped to A$460,397, while operating expenses fell sharply and cash stood at A$11.2 million. The battery materials and life sciences company says customer evaluations and partnership discussions are building, but most opportunities remain short of recurring commercial revenue.